Successful alectinib treatment for carcinoma of unknown primary with eml4‐alk fusion gene: A case report

Abstract

Gene alteration in anaplastic lymphoma kinase (ALK) is rare, and the efficacy of ALK inhibitors in the treatment of carcinoma of unknown primary (CUP) with ALK alteration remains unclear. The patient was a 56‐year‐old woman who presented with cervical lymph node swelling. Computed tomography revealed paraaortic, perigastric, and cervical lymph node swelling; ascites; a liver lesion; and a left adrenal mass. A cervical lymph node biopsy was performed, and pathological diagnosis of an undifferentiated malignant tumor was conducted. Finally, the patient was diag-nosed with CUP and treated with chemotherapy. To evaluate actionable mutations, we performed a multigene analysis, using a next‐generation sequencer (FoundationOne® CDx). It revealed that the tumor harbored an echinoderm microtubule‐associated protein‐like 4 (EML4) and ALK fusion gene. Additionally, immunohistochemistry confirmed ALK protein expression. Alectinib, a potent ALK inhibitor, was recommended for the patient at a molecular oncology conference at our institution. Accordingly, alectinib (600 mg/day) was administered, and the multiple lesions and symptoms rap-idly diminished without apparent toxicity. The administration of alectinib continued for a period of 10 months without disease progression. Thus, ALK‐tyrosine kinase inhibitors should be consid-ered in patients with CUP harboring the EML4‐ALK fusion gene.